10-K: Organogenesis Reports Strong 2025 Revenue Growth Amidst Regulatory Shifts

Organogenesis Holdings Inc. reported a significant increase in net product revenue for fiscal year 2025, driven by Advanced Wound Care products, while navigating evolving Medicare reimbursement policies and advancing its ReNu BLA submission.

Summary

• Net product revenue increased by 17% to $563.0 million in 2025 from $482.0 million in 2024.
• Advanced Wound Care product revenue increased by 17% to $531.2 million in 2025, primarily due to newly licensed products.
• Surgical & Sports Medicine product revenue increased by 12% to $31.8 million in 2025, due to an increase in certain customer buying patterns.
• Gross profit increased by 16% to $425.5 million in 2025, driven by a shift in product mix.
• Operating income was $44.7 million in 2025, a significant improvement from an operating loss of $1.3 million in 2024.
• Net income was $37.0 million in 2025, compared to $0.9 million in 2024.
• Adjusted EBITDA increased to $98.1 million in 2025 from $49.8 million in 2024.
• The company initiated a rolling Biologics License Application (BLA) submission for ReNu for knee osteoarthritis, expected to be completed in the first half of 2026.
• Manufacturing of Dermagraft remains suspended, with plans to resume sales by the end of 2027 from a new Smithfield, Rhode Island facility.
• CMS implemented new Medicare payment policies for skin substitute products effective January 1, 2026, with a single initial payment rate of approximately $127.14 per square centimeter for non-BLA skin substitutes, which could materially and adversely impact utilization, revenue, and profitability.
• The company is experiencing a significant year-over-year decline in revenue in the first quarter of fiscal year 2026 due to CMS reimbursement changes and clinician confusion regarding discarded product comments.
• A $5.0 million grant from a governmental agency was received in Q2 2025 for the Smithfield Facility, with $1.1 million recognized as income in 2025.
• A $11.2 million write-down to fair value for an asset held for sale (a purchased building) was recorded in 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While 2025 showed strong revenue and profit growth, the significant Q1 2026 revenue decline due to Medicare reimbursement changes and the ReNu Phase 3 trial setback introduce considerable near-term uncertainty and risk.

Positives

• Net product revenue increased by 17% to $563.0 million in 2025.
• Advanced Wound Care revenue grew by 17% to $531.2 million in 2025, primarily due to newly licensed products.
• Operating income significantly improved to $44.7 million in 2025 from a loss of $1.3 million in 2024.
• Net income increased to $37.0 million in 2025 from $0.9 million in 2024.
• Adjusted EBITDA nearly doubled to $98.1 million in 2025 from $49.8 million in 2024.
• Successfully remediated previously reported material weaknesses in internal control over financial reporting as of December 31, 2024.
• Initiated a rolling Biologics License Application (BLA) submission for ReNu, expected to be completed in the first half of 2026.
• Shareholders approved the issuance of Class A common stock upon conversion of Convertible Preferred Stock in excess of Nasdaq limitations in Q2 2025, removing cash-in-lieu payment obligations.
• Secured a new 122,000 sq ft biomanufacturing facility in Smithfield, RI, expected to commence manufacturing Dermagraft, Apligraf, and PuraPly in 2027, leading to substantial long-term cost savings.
• Received RMAT designation for ReNu for knee OA, which may expedite development and review.
• Maintained compliance with all covenants under the 2021 Credit Agreement as of December 31, 2025.
• Received a $5.0 million government grant for the Smithfield Facility in Q2 2025.

Negatives

• Experiencing a significant year-over-year decline in revenue in Q1 2026 due to CMS updated 2026 Medicare reimbursement changes and clinician confusion regarding discarded product comments.
• The second Phase 3 Randomized Controlled Trial (RCT) of ReNu did not achieve statistical significance for its primary endpoint.
• Dermagraft manufacturing and sales remain suspended since Q4 2021 and Q2 2022, respectively, with resumption not expected until the end of 2027.
• CMS finalized new payment policies for skin substitute products effective January 1, 2026, which could materially and adversely impact utilization, revenue, and profitability.
• Implementation of the WISeR Model (technology-enabled prior authorization) in six states starting January 1, 2026, could impact beneficiary access and negatively affect utilization, revenue, and profitability.
• A $11.2 million write-down to fair value for an asset held for sale was recorded in 2025.
• Net cash used in operating activities was $10.3 million in 2025, compared to net cash provided of $14.2 million in 2024.
• Increased accounts receivable by $115.8 million and inventories by $17.9 million in 2025.
• The company's stock price has been, and is likely to continue to be, volatile.
• Most of the key patents related to marketed products (Apligraf, Dermagraft, NuShield) are expired.

Risks

• Uncertainty and potential adverse changes in coverage and adequate reimbursement for products from government payers, private health insurers, and other third-party payers, including new or revised Medicare Local Coverage Determinations (LCDs).
• Dependence on major contracts with Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs), with cost-containment efforts potentially affecting business.
• Legal exposure for non-compliance with reporting and payment obligations under governmental pricing programs, including additional rebate/discount requirements, fines, sanctions, and litigation.
• Risk of future material weaknesses or significant deficiencies in internal control over financial reporting, despite remediation of a previously reported material weakness.
• Significant and continuing competition, which could adversely affect business, results of operations, and financial condition.
• Rapid technological change could cause products to become obsolete if product offerings are not enhanced through R&D.
• Failure to convince physicians of product safety and efficacy compared to existing treatments.
• Risk of FDA determining that certain products (Affinity, Novachor, NuShield) do not qualify for regulation solely under Section 361 of the PHSA, potentially requiring revised labeling/marketing or suspension of sales until FDA approval.
• Dependence on a limited group of suppliers and manufacturers, risking significant product development costs or material delivery delays if supply is interrupted.
• Uncertainty and adverse changes in general economic conditions, including turmoil in the global banking system, may negatively affect business.
• Operating results may fluctuate significantly due to factors outside control, with potential for future losses despite recent net income.
• Significant disruptions of information technology systems or breaches of information security could adversely affect business.
• Patents and other intellectual property rights may not adequately protect products, and most key patents for marketed products are expired.
• Transactions with related parties present possible conflicts of interest.
• Enacted or future legislation, regulatory reform, or healthcare reform initiatives may reduce federal funding or place downward pressure on product prices/reimbursement.
• The outstanding Series A Convertible Preferred Stock reduces the relative voting power and dilutes ownership of Class A common stockholders, and may adversely affect the market price.
• Holders of Convertible Preferred Stock have special rights to influence the company and its board of directors.
• Convertible Preferred Stock has preferential rights over Class A common stock, which could adversely affect liquidity and financial condition.
• Concentration of ownership of capital stock (54.1% by certain affiliates as of Dec 31, 2025) limits other stockholders' ability to influence corporate matters and could delay/prevent a change of control.
• Risk of product liability claims.
• Interruptions in the supply of products or inventory loss.
• Increased prices for, or unavailability of, raw materials.
• Inability to retain key employees, consultants, and advisors.
• Changes in accounting standards and subjective assumptions, estimates, and judgments by management.
• Failure to comply with environmental, health, and safety laws and regulations.
• Unanticipated changes in effective tax rates or adverse outcomes from tax return examinations.
• Lack of a sustained active trading market for securities.
• Failure to meet Nasdaq continued listing requirements.
• Changes to trade policy, including tariff and customs regulations.

Future Outlook

The company expects to complete its rolling Biologics License Application (BLA) submission for ReNu in the first half of 2026 and plans to resume Dermagraft sales by the end of 2027 from its new Smithfield, RI facility. Management anticipates that current cash, working capital, and revolving facility availability will be sufficient to fund operations for at least 12 months beyond the filing date. The company plans to continue investing in market development, sales force expansion, and R&D for new products and expanded payer coverage. However, CMS intends to propose differentiated payment rates for skin substitutes in future years, and the company expects continued increases in selling, general, and administrative expenses.

Management Comments

• We believe CMS finalized PFS and OPPS payment structure will curb abuse under the current system and the resulting rapid escalation in Medicare spending, and ensure a much-needed consistent payment approach across sites of care.
• While the longer-term impact of CMS updated 2026 Medicare reimbursement changes is still uncertain, we are experiencing a significant year-over-year decline in revenue in the first quarter of fiscal year 2026.
• Our mission is advancing healing and recovery beyond expectations.
• We believe that our data and regulatory approvals provide us with a strong competitive advantage.
• We believe that providing these essential support services in-house creates a competitive advantage by allowing us to align our support services with our sales efforts leading to improvements in the overall customer experience.
• We believe that diversity and inclusion in the workplace enhance employee engagement and stimulate innovation, and that people in diverse groups work better, share information more broadly and consider a wider range of views.
• We aim to maintain an 'open door' culture, and encourage employees to voice their concerns, questions, suggestions and comments.
• We aim to foster a culture where learning is continuous, and we strive to promote from within.
• We recognize the benefits of a healthy workforce and offer our employees the opportunity to participate in wellness activities and programs throughout the year.
• We prioritize the health and safety of our employees.

Industry Context

StockSavvy.ai notes that Organogenesis operates in the highly competitive and rapidly evolving regenerative medicine and advanced wound care markets. The industry is characterized by significant R&D investment, stringent regulatory pathways (FDA 510(k), PMA, BLA, and 361 HCT/Ps), and complex reimbursement landscapes. The company's focus on both Advanced Wound Care and Surgical & Sports Medicine aligns with broader trends of addressing aging demographics and increasing comorbidities like diabetes and obesity, which drive demand for advanced healing solutions. The recent CMS policy changes and the introduction of the WISeR Model reflect a broader industry trend towards cost containment and value-based care, which could significantly impact all players in the skin substitute market. The company's strategy to prioritize certain products and invest in clinical data generation is a common response to these evolving market dynamics.

Comparison to Industry Standards

• Organogenesis's Apligraf is noted as the only product to date with PMA approval for both Venous Leg Ulcers (VLUs) and Diabetic Foot Ulcers (DFUs), and the leading skin substitute product for VLUs, demonstrating a strong competitive position in this specific segment.
• Dermagraft also has PMA approval for DFUs and studies have demonstrated its superior clinical efficacy and value compared to competitive wound care products and conventional therapy.
• The company highlights its unique position as one of the few regenerative medicine companies offering PMA approved and 510(k) cleared products in addition to 361 HCT/Ps, suggesting a broader regulatory compliance and product validation compared to many competitors in the placental-based and allograft tissue field, which has lower barriers to entry.
• The company's RMAT designation for ReNu for knee OA positions it alongside other innovative therapies seeking expedited regulatory pathways, though the second Phase 3 trial's lack of statistical significance for its primary endpoint indicates the inherent challenges in late-stage clinical development, even for promising candidates.

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings.
• May become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business (intellectual property, employment, general claims).
• Management believes the ultimate resolution of such claims would not have a material adverse effect on financial position, operating results, or cash flows.
• The outcome of legal matters is inherently unpredictable and subject to significant uncertainties.

Related Party Transactions

• Lease obligations to affiliates for Canton, Massachusetts facilities (65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC). Owners of these entities are also directors, former directors, and/or stockholders of the company.
• In November 2024, the company repurchased 7,921,731 shares of Class A common stock from certain existing stockholders, including certain directors and their affiliates.
• In November 2024, the company entered into a subscription agreement with Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. (now related parties) for 130,000 shares of Series A Convertible Preferred Stock.
• The director designated by the Investors (holders of Convertible Preferred Stock) may have interests that diverge from other shareholders.

Stakeholder Impact

• Shareholders (Class A Common Stock): Experienced dilution of voting power and ownership due to Convertible Preferred Stock, with potential adverse impact on market price from future conversion/sale. Face risk of significant Q1 2026 revenue decline.
• Shareholders (Convertible Preferred Stock): Benefit from senior ranking for dividends and liquidation preference, an 8.0% per annum dividend, and significant influence over corporate governance and strategic decisions.
• Employees: Benefit from a commitment to diversity and inclusion, competitive compensation and benefits, continuous learning, and health and safety programs, but have been impacted by restructuring plans in 2023 and 2025.
• Customers (Hospitals, Wound Care Centers, etc.): Benefit from a broad product portfolio and in-house customer support, but face potential negative impacts on product utilization and access due to CMS reimbursement changes and cost-containment efforts by GPOs/IDNs.
• Suppliers: Face risks of supply disruption due to the company's dependence on a limited group of suppliers for critical components and human tissue, and potential for less favorable credit terms.
• Creditors: The company was in compliance with all covenants under the 2021 Credit Agreement as of December 31, 2025, but preferential rights of Convertible Preferred Stock could affect liquidity and ability to obtain additional financing.

Next Steps

• Complete the rolling Biologics License Application (BLA) submission for ReNu in the first half of 2026.
• Transition Dermagraft manufacturing to the new Smithfield, Rhode Island biomanufacturing facility, with expected commencement in 2027.
• Resume sales of Dermagraft by the end of 2027.
• Continue to invest in physician and payer education, preclinical and clinical trials, real-world evidence, and other research to confirm product benefits.
• Seek expanded payer coverage for PuraPly AM/XT, Novachor, NuShield, and Affinity.
• Launch new products from the robust pipeline in both Advanced Wound Care and Surgical & Sports Medicine markets in the next few years.
• Develop additional smaller sizes of Apligraf and Dermagraft, requiring several years for development and FDA PMA Supplement approval.
• Expand sales outside the United States, including the European Union and the Middle East.
• Evaluate tuck-in acquisitions that complement existing portfolios.
• Dedicate resources to comply with the new FDA QSR final rule, effective February 2, 2026.
• The MACs will issue updated LCDs (though previous ones were withdrawn).
• CMS intends to propose payment rates that differentiate between the three FDA regulatory categories for skin substitutes in future years.
• CMS is testing the Wasteful and Inappropriate Service Reduction (WISeR) Model in six states for five years.

Key Dates

Recommendation

Organogenesis demonstrated strong revenue and profit growth in 2025, driven by its Advanced Wound Care segment and strategic product licensing. The initiation of the ReNu BLA submission and the new manufacturing facility are positive long-term developments. However, the significant year-over-year revenue decline expected in Q1 2026 due to adverse Medicare reimbursement changes and the setback in the second ReNu Phase 3 trial introduce substantial near-term headwinds and uncertainty. The company faces ongoing regulatory risks and intense competition. Given the mixed signals—strong past performance versus significant future challenges and uncertainties—a 'hold' recommendation is appropriate as investors should monitor how the company navigates the evolving reimbursement landscape and progresses its pipeline.

Keywords

Regenerative Medicine, Wound Care, Surgical & Sports Medicine, Biologics, Skin Substitutes, SEC Filing, 10-K, Organogenesis, ORGO, Healthcare, Biotechnology, Medical Devices, FDA Approval, Medicare Reimbursement, Convertible Preferred Stock, Financial Results, Annual Report